Clik here to view.
Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from...
SAN FRANCISCO Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse...
View ArticleClik here to view.
Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS®...
SAN FRANCISCO Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin)...
View ArticleClik here to view.
Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at...
SHANGHAI Generon (Shanghai) Corporation, a leading biopharmaceutical company in China, today announced the presentation of the global Phase II study results for F-627 (benegrastim) at the American...
View ArticleClik here to view.
Integra Holdings Closes $3 Million Investment from Guangxi Wuzhou...
JERUSALEM Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, announced today that it has received US $3 million...
View ArticleClik here to view.
武田宣布成立武田肿瘤部，以加强突破性抗癌药的发现、开发和全球商业化
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE:4502)今天宣布，其总部位于马萨诸塞州剑桥的全球肿瘤业务部将命名为武田肿瘤部(Takeda...
View ArticleClik here to view.
Mazor Robotics Receives Purchase Orders for Three Renaissance® Systems in Asia
CAESAREA, Israel Mazor Robotics Ltd. (NASDAQGM: MZOR) (TASE: MZOR), a developer of innovative guidance systems and complementary products, today announced that it received a purchase order for two...
View ArticleClik here to view.
Gynesonics Announces Another Peer-Reviewed Publication and Presentation of...
REDWOOD CITY, Calif. Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, today announced the recent...
View ArticleClik here to view.
武田薬品が画期的ながん治療薬の創薬・開発と世界的規模での商業化の促進に向けて企業名Takeda Oncologyを確立と発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502）は本日、米マサチューセッツ州ケンブリッジに本社を置く当社のGlobal Oncology Business Unitが、企業名をTakeda Oncologyとすると発表しました。Takeda...
View ArticleClik here to view.
Seattle Genetics和武田在ASH年会上报告ADCETRIS® (Brentuximab...
旧金山 (美国商业资讯) — Seattle Genetics, Inc. (Nasdaq: SGEN)与武田药品工业株式会社(TSE:4502)今天报告的数据显示，自体干细胞移植(ASCT)后有复发风险的霍奇金淋巴瘤(HL)患者，在ASCT后立即接受ADCETRIS (brentuximab...
View ArticleClik here to view.
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce...
TOKYO & OSAKA, Japan & NEW YORK Ono Pharmaceutical Co.,Ltd. (Tokyo: 4528), Bristol-Myers Squibb Company (NYSE:BMY) and Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151,“Kyowa Hakko Kirin”) announced...
View ArticleClik here to view.
Seattle Genetics和武田在ASH年会上发布ADCETRIS® (Brentuximab...
旧金山 (美国商业资讯) — Seattle Genetics, Inc. (Nasdaq: SGEN)与武田药品工业株式会社 (TSE:4502)今天发布了ADCETRIS (brentuximab vedotin)治疗复发或难治全身性间变性大细胞淋巴瘤(ALCL)枢纽性2期临床试验的4年总生存(OS)数据。ADCETRIS是一种靶向作用于CD30的抗体药物轭合物...
View ArticleClik here to view.
エリテック、急性リンパ芽性白血病を対象とするERY-ASP/GRASPA®の臨床試験で別の良好な第III相の結果を報告
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック（Paris:ERYP）（Euronext Paris: FR0011471135 –...
View ArticleClik here to view.
Macrogen to Supply ‘X-Genome’ Genome Analysis Service to Institute of...
SEOUL, South Korea Customized medicine & biotechnology company Macrogen Inc. (CEO HyungTae Kim, www.macrogen.com) announced that it has made an agreement to supply the company’s X-Genome...
View ArticleClik here to view.
Aerocrine Resumes Sales and Marketing of NIOX MINO® in China after...
SOLNA, Sweden Regulatory News: Aerocrine AB (STO:AERO-B), a leader in products to monitor and manage airway inflammation associated with Asthma, announced today that its handheld airway inflammation...
View ArticleClik here to view.
Article 1
ボストン （ビジネスワイヤ） — 米国マサチューセッツ州ボストンに本社を置く臨床ステージの総合医薬品研究開発会社 Boston Strategics...
View ArticleClik here to view.
Independent Study Demonstrates Stroke Patients Experience Superior Outcomes...
ALAMEDA, Calif. Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that...
View ArticleClik here to view.
Allegro Ophthalmics and Hanmi Pharmaceutical Announce Strategic Investment...
SAN JUAN CAPISTRANO, Calif. & SEOUL, South Korea Allegro Ophthalmics, LLC, and Hanmi Pharmaceutical Co., Ltd. today announced that they have entered into a license agreement for Luminate®...
View ArticleClik here to view.
ALung Receives Marketing Clearance for Hemolung RAS in Australia
PITTSBURGH ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, today...
View ArticleClik here to view.
Cell Therapy Catapult Licenses Nobel Prize-Winning Intellectual Property for...
LONDON & KYOTO, Japan The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation’s health and wealth, has signed a patent licence...
View ArticleClik here to view.
PharmaEngine Announces Expanded Analyses of Phase 3 MM-398 NAPOLI-1 Study...
TAIPEI, Taiwan PharmaEngine, Inc. (TWO: 4162) today announced that the additional analyses from the global phase 3 NAPOLI-1 study of MM-398 (PEP02, liposome irinotecan injection) in metastatic...
View Article